News Article | April 27, 2017
The Lebanese Petroleum Administration (LPA) has designated eight more international companies “prequalified” for an offshore licensing round with bids due Sept. 15.
News Article | May 2, 2017
The forces of military strongman Khalifa Haftar control much of eastern Libya (AFP Photo/Abdullah DOMA) Tripoli (AFP) - The head of Libya's UN-backed unity government on Tuesday held a rare meeting with a military strongman who supports a rival authority in the violence-wracked country, official media said. Fayez al-Sarraj and Field Marshal Khalifa Haftar met face-to-face in Abu Dhabi, the LANA news agency said, for only the second time since Sarraj was named prime minister-designate in late 2015. Sarraj and Haftar met "thanks to international and Arab mediation", according to LANA, which is loyal to the parliament based in eastern Libya, after a first meeting in January last year. Libyan television broadcaster 218 reported that the two held talks "in private" after posing for a photograph together. Political rivalry and fighting between militias has hampered Libya's efforts to recover from the chaos that followed the 2011 uprising that toppled and killed longtime dictator Moamer Kadhafi. Haftar, who backs an administration based in the far east of the country, has refused to recognise the authority of the UN-backed Government of National Accord since it started working in Tripoli in March last year. In February, Sarraj said Haftar had refused to meet him in person in Cairo for Egypt-backed talks to discuss possible amendments to a UN-backed agreement signed in late 2015 that gave birth to the fragile unity government. The Libya Political Agreement (LPA) gave no role in Libya's future to Haftar, whose forces control much of the country's east. But Haftar, the head of the self-styled Libyan National Army, has since established himself as a key player, especially after seizing the country's key oil terminals in September. Mattia Toaldo, senior policy fellow at the European Council on Foreign Relations, said Tuesday's meeting came after a change of tack from Haftar, who seeks nationwide presidential polls next year. Haftar is "now pursuing a different strategy... exchanging his support for an amended LPA for a guarantee to have presidential elections early in 2018 in which it would be thinkable for him to run", Toaldo said. The meeting also comes as Sarraj seeks "badly needed legitimisation" from the eastern authorities, even as he struggles with internal support in western Libya where factions are hostile to Haftar, he said. "I doubt that anything negotiated by Sarraj would be accepted peacefully by factions in western Libya if it is seen as giving Haftar a too prominent position within the security sector or the political system," Toaldo said.
News Article | May 8, 2017
IMAGE: Rice University's latest new dual-function bioscilloscope uses a light plate apparatus, or LPA, that is outfitted with the spectral LEDs. view more Rice University bioengineers who specialize in creating tools for synthetic biology have unveiled the latest version of their "biofunction generator and "bioscilloscope," an optogenetic platform that uses light to activate and study two biological circuits at a time. The biofunction generator and bioscilloscope are a toolkit of genes and hardware that use colored lights and engineered bacteria to bring both mathematical predictability and cut-and-paste simplicity to the world of genetic circuit design. "Unfortunately, all biological light sensors are 'sloppy,' in that they tend to respond to multiple colors of light," said Jeffrey Tabor, an associate professor of bioengineering at Rice. "We've developed a detailed mathematical model to capture this sloppiness and design multicolor light signals that compensate for it so that two light sensors can be independently controlled in the same cell. Because most of the circuits that control biological behaviors are composed of two or more genes, this technology will make it easier for our lab and others to study complex synthetic biological systems." The research is described in a recent paper in Molecular Systems Biology. Life is controlled by DNA-based circuits. These are similar to the circuits in smartphones and other electronic devices with a key difference: The information that flows through electronic circuitry is voltage, and the information that flows through genetic circuits is protein production. Genetic circuits can be switched on or off -- produce protein or not -- and they can be tuned to produce more or less protein, much like voltage from an electronic circuit can be raised or lowered. The biofunction generator and bioscilloscope, which were first created in Tabor's lab three years ago, show how closely the analogy holds. Function generators and oscilloscopes, stock components of electrical engineering labs for more than 50 years, are test instruments that can feed voltage signals into circuits and show how signal voltage varies with time at other locations within the circuit. Oscilloscope screens usually show wave functions and can plot one or more signals at a time. The bioscilloscope plots the output of biocircuits in exactly the same way. The inputs and outputs for the biocircuits are light. Specifically, Tabor's team has developed a biofunction generator, a set of light-activated genes that can be used to turn genes on and off and to regulate the amount of protein they produce when turned on. The bioscilloscope comprises another set of genes that add fluorescent tags to the DNA to read out the circuit response, which means the more protein that's produced, the more light that's given off by the sample. In the new paper, recent Ph.D. graduate and lead author Evan Olson and colleagues tested new dual-function tools using the latest optogenetic hardware and software tools developed by Tabor's lab in conjunction with a new mathematical model for the biofunction generator output. "The model allows us to predict the output gene-expression response to any light input signal, regardless of how the intensity or spectral composition of the light signal changes over time," Olson said. "The model works by describing how light of any wavelength and intensity is converted into a population of light sensors in the 'on' or 'off' states." Olson said they demonstrated the system in two proof-of-concept experiments. In the first, they showed the system could compensate for "perturbative" signals, incoming light such as that from a microscope or fluorescent imager that might otherwise interfere with the incoming optogenetic signal. In the second, they demonstrated multiplexed control by simultaneously driving two independent gene expression signals in two optogenetic circuits in the same bacteria. The output on the bioscilloscope shows the two functions as red and green lines. The researchers showed they could activate the genetic circuits to produce smooth waves and stair-step patterns, and they showed the two circuits could be switched on in unison or at different times. "This multiplexing approach enables a completely new generation of experiments for characterizing and controlling the biological circuits that integrate multiple signals and that are ubiquitous in biological networks, particularly those used for decision-making and developmental processes," Tabor said. The study was co-authored by undergraduate Constantine Tzouanas. The research was supported by the Office of Naval Research and the National Science Foundation. The DOI of the Molecular Systems Biology paper is: 10.15252/msb.20167456 A copy of the paper is available at: http://msb. It's now easier to go with the flow -- May 3, 2016 http://news. No bioengineered gut bacteria, no glory -- May 12, 2014 http://news. This release can be found online at news.rice.edu. Located on a 300-acre forested campus in Houston, Rice University is consistently ranked among the nation's top 20 universities by U.S. News & World Report. Rice has highly respected schools of Architecture, Business, Continuing Studies, Engineering, Humanities, Music, Natural Sciences and Social Sciences and is home to the Baker Institute for Public Policy. With 3,879 undergraduates and 2,861 graduate students, Rice's undergraduate student-to-faculty ratio is 6-to-1. Its residential college system builds close-knit communities and lifelong friendships, just one reason why Rice is ranked No. 1 for happiest students and for lots of race/class interaction by the Princeton Review. Rice is also rated as a best value among private universities by Kiplinger's Personal Finance. To read "What they're saying about Rice," go to http://tinyurl. .
News Article | February 28, 2017
SAN JOSE, Calif., Feb. 28, 2017 /PRNewswire/ -- Highlights: Imec validates Cadence LPA PLUS for advanced-process technologies Customers can verify design manufacturability during implementation and signoff, enabling them to detect and fix yield-limiting lithography...
News Article | November 1, 2016
Abstract: Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) will make presentations at the following upcoming events: The 25th Annual Credit Suisse Healthcare Conference - Scottsdale, AZ, November 6-8, 2016 November 7, 11:30 a.m. MST - Christopher Anzalone, Ph.D., Arrowhead president and CEO will deliver a corporate presentation The Liver Meeting® 2016, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) - Boston, November 11-15, 2016 November 13, 5:30 p.m. EST - Christine Wooddell, Ph.D., Arrowhead director of liver targeting will deliver an oral presentation titled, "RNA interference therapeutic ARC-AAT prevents production of Z-alpha1 antitrypsin polymers and reverses liver disease phenotype in PiZ mouse model" November 13, 8:00 a.m. EST - Alice Turner, MBChB (Hons), MRCP, PGCE (MedEd), PhD, University of Birmingham, Edgbaston Birmingham, United Kingdom, and coauthors, will deliver a late-breaking poster presentation titled, "RNA interference (RNAi) with ARC-AAT provides deep and prolonged knockdown of alpha-1 antitrypsin levels in healthy volunteers" American Heart Association's Scientific Sessions 2016 - New Orleans, November 12-16, 2016 November 14, 10:40 a.m. CST - Stacey Melquist, Ph.D., Arrowhead senior scientist will deliver an oral presentation titled, "Targeting factor XII (F12) with a novel RNAi delivery platform as a prophylactic treatment for thromboembolism" November 14, 2:00 p.m. CST - Stacey Melquist, Ph.D., Arrowhead senior scientist will deliver an oral presentation titled, "Targeting apolipoprotein(a) with a novel RNAi delivery platform as a prophylactic treatment to reduce risk of cardiovascular events in individuals with elevated lipoprotein (a)" The 28th Annual Piper Jaffray Healthcare Conference - New York, November 29-30, 2016 November 30, 8:30 a.m. EST - Christopher Anzalone, Ph.D., Arrowhead president and CEO will deliver a corporate overview in a fireside chat with Ted Tenthoff, senior research analyst, Piper Jaffray Copies of presentation materials and webcasts can be accessed on the Events and Presentations page under the Investors section of the Arrowhead website after each presentation is delivered. About Arrowhead Pharmaceuticals, Inc. Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing. The company's pipeline includes ARC-520 and ARC-521 for chronic hepatitis B virus infection, ARC-AAT for liver disease associated with alpha-1 antitrypsin deficiency, ARC-F12 for hereditary angioedema and thromboembolic disorders, ARC-LPA for cardiovascular disease, and ARC-HIF2 for renal cell carcinoma. For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit ir.arrowheadpharma.com/alerts.cfm. About ARC-AAT Arrowhead's ARC-AAT is being investigated for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD), a rare genetic disease that severely damages the liver and lungs of affected individuals. The mean estimated prevalence of AATD in the U.S. is 1 per 3000-5000, or approximately 100,000 patients. AATD is also an important cause of pediatric liver disease with an estimated prevalence in children of approximately 20,000 patients, and 50-80% likely to manifest liver disease during childhood. It is a rare disease that is frequently misdiagnosed or undiagnosed. ARC-AAT employs a novel unlocked nucleobase analog (UNA) containing RNAi trigger molecule designed for systemic delivery using the Dynamic Polyconjugate delivery system. ARC-AAT is highly effective at knocking down the alpha-1 antitrypsin (AAT) gene transcript and reducing the hepatic production of the mutant AAT (Z-AAT) protein in animal studies. Reduction of liver production of the inflammatory Z-AAT protein, which is believed to be the cause of progressive liver disease in AATD patients, is important as it is expected to halt the progression of liver disease. ARC-AAT was granted orphan drug designation in both the United States and in Europe, the latter being held on Arrowhead's behalf by a local EU representative Pharma Gateway AB. Arrowhead is conducting a Phase 1 clinical study of ARC-AAT, with part A in healthy volunteers (now complete) and part B in AATD patients, and a Phase 2 multiple dose study in AATD patients. About ARC-F12 Arrowhead's RNAi-based candidate ARC-F12 is in preclinical development as a potential treatment for factor XII (F12) mediated diseases. Arrowhead sees clear unmet need in hereditary angioedema (HAE) and thromboembolic diseases. The biology of factor 12 as part of the coagulation cascade and the kinin-kallikrein system suggest that its reduction through RNAi may present opportunities in both disease areas. The company is currently conducting studies in order to advance ARC-F12 into clinical trials. About ARC-LPA Arrowhead's RNAi-based candidate ARC-LPA is in preclinical development as a potential treatment for cardiovascular diseases. ARC-LPA is designed to reduce production of apolipoprotein(a), a key component of lipoprotein(a), or Lp(a). Lp(a) levels in humans are genetically defined and higher levels correlate with increased risk of cardiovascular diseases, independent of cholesterol and LDL levels. ARC-LPA is Arrowhead's first drug candidate to use a subcutaneously administered delivery construct. Safe Harbor Statement under the Private Securities Litigation Reform Act: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances. DYNAMIC POLYCONJUGATES is a trademark of Arrowhead Pharmaceuticals, Inc. For more information, please click If you have a comment, please us. Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
News Article | September 7, 2016
Home > Press > Arrowhead Pharmaceuticals Doses First Patient with Hepatitis B in Multiple Ascending Dose Portion of Phase 1/2 Study of ARC-521 Abstract: Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in the multiple ascending dose (MAD) portion of its ongoing Phase 1/2 study of ARC-521, the company's second RNAi-based investigational medicine for the treatment of chronic hepatitis B virus (HBV) infection. To date 24 healthy volunteers have been treated in the study, and the drug safety committee (DSC) approved initiation of the MAD after a planned review of safety data from cohort 3 of the healthy volunteer portion of the study. The MAD is designed to evaluate the safety, tolerability, and antiviral activity of single and multiple doses of ARC-521 in patients with chronic HBV. Bruce Given, M.D., chief operating officer and head of R&D at Arrowhead said, "The innovative design for the first-in-man study of ARC-521 is intended to get to multiple dose data in patients rapidly. Arrowhead's development staff and the experienced investigators working on the study are operating at best-in-class speeds, enabling us to begin the MAD portion of the study just three months into the clinical program. This study may have multiple readouts, including single dose safety data in healthy volunteers and single and multiple dose safety and antiviral activity data in HBV patients. These readouts should happen progressively, potentially starting during the first quarter of 2017." The MAD portion of the ARC-521 study (ARC5211001) is a multicenter, sequential, multiple dose, open label study in patients with chronic HBV. Up to 24 chronic HBV patients (8 patients per dose level) that are negative for Hepatitis B e-antigen (HBeAg) at screening will enroll sequentially into up to 3 dose levels (2 mg/kg, 4 mg/kg, 6 mg/kg) to receive 3 monthly doses of open label ARC-521. About ARC-521 Arrowhead's ARC-521 is being investigated for its potential to produce functional cures in patients with chronic hepatitis B virus (HBV) infection. ARC-521 intervenes upstream of the reverse transcription process where current standard-of-care nucleotide and nucleoside analogs act, and is designed to silence the production of all HBV gene products. The small interfering RNAs (siRNAs) in ARC-521 engage the body's normal cellular RNAi machinery and direct specific cleavage of HBV RNA transcripts, thereby reducing the levels of HBV proteins and the RNA template used to produce viral DNA. Designed to complement ARC-520, ARC-521 is a second generation HBV candidate that targets HBV mRNA transcripts from both cccDNA and integrated DNA and is expected to be most suitable for those patients who tend to have lower levels of viral cccDNA. Arrowhead is investigating ARC-521 specifically to determine if significantly reducing circulating and non-circulating viral proteins and RNA will allow for re-constitution of an effective host immune response and ultimately HBsAg seroclearance resulting in functional cure. As many as 350-400 million people worldwide are chronically infected with the hepatitis B virus, which can lead to cirrhosis of the liver and is responsible for 80% of primary liver cancers globally. Arrowhead is conducting a Phase 1/2 single and multiple dose study in healthy volunteers and HBV patients. About Arrowhead Pharmaceuticals, Inc. Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing. The company's pipeline includes ARC-520 and ARC-521 for chronic hepatitis B virus infection, ARC-AAT for liver disease associated with alpha-1 antitrypsin deficiency, ARC-F12 for hereditary angioedema and thromboembolic disorders, ARC-LPA for cardiovascular disease, and ARC-HIF2 for renal cell carcinoma. For more information please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit ir.arrowheadpharma.com/alerts.cfm. Safe Harbor Statement under the Private Securities Litigation Reform Act: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances. DYNAMIC POLYCONJUGATES is a trademark of Arrowhead Pharmaceuticals, Inc. For more information, please click If you have a comment, please us. Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
News Article | November 3, 2016
On November 2, 2016 the State JSC “Privatisation Agency” organized its Investor Conference Online Webinar on auctions of state-owned shares of JSC “Valmieras stikla šķiedra” and JSC “Grindeks” that will take place on November 8, 2016 (more information here). The recorded webinar is available online: http://ej.uz/LPA_webinar, and the presentation, demonstrated during the webinar, is available in the attachment. About the State JSC “Privatisation Agency” The State JSC “Privatisation Agency” ensures the governance, privatisation and alienation of the state-owned shares. Within the framework of implementing the SOE governance reform, the state participation in enterprises wherein the state has no strategic interest is being gradually decreased. During the 1st half of 2016 the State JSC “Privatisation Agency” held state owned shares in 39 capital companies, incl. in stock market listed companies JSC “Valmieras stikla šķiedra”, JSC “Grindeks” and JSC “Latvian Shipping”.
News Article | February 28, 2017
San Jose, California, 28 February 2017 - ASML Holding NV (ASML) today announced a partnership with Cadence Design Systems, Inc. to expand the capabilities of its holistic lithography product portfolio, further streamlining chipmakers' process flow from design to mask production. The collaboration will bring together ASML's computational lithography solutions and the Cadence physical design back-end tools, leading to enhanced Design Technology Co-Optimization (DTCO) capabilities for advanced nodes, and other technologies. "In the face of shrinking process nodes, engineers are increasingly relying on designer-friendly, production-accurate manufacturability checks throughout the design phase to realize tighter imaging performance and cycle time goals," said Dr. Anirudh Devgan, senior vice president and general manager of the Digital & Signoff Group and the System & Verification Group at Cadence. "Together with ASML, we are now able to efficiently bridge the gap between design and manufacturing, empowering our customers to take better control of their design intent, reliability and yield through improved lithography awareness capabilities." As part of its holistic lithography approach, ASML has developed powerful lithography and patterning models that can simulate how a chip design is realized in silicon, representing the actual manufacturing processes. The integration of these design models into Cadence products enables DTCO to deliver optimal design scaling while securing manufacturability and yield. As the first result of their collaboration, the newly released Cadence® LPA PLUS enables engineers to simulate the manufacturability of their design at any time during implementation and signoff, enabling more efficient delivery of high-quality designs. ASML's partnership with Cadence represents another major step toward realizing a full end-to-end design-to-mask process flow. When combined with an earlier partnership with NCS, engineers can now leverage litho-aware design and mask data preparation on a seamlessly integrated platform. "Since ASML's early days, we've developed our systems in a cooperative network of partners, a practice we call Open Innovation," said Christophe Fouquet, Executive Vice President of Applications at ASML. "This enables us to remain focused on developing our core holistic lithography technology leadership in modeling, scanner imaging and patterning process control, while leveraging our partnerships to deliver improved cycle time and productivity along the whole value chain from design technology development to production implementation of the physical design, mask design, and mask data preparation." About ASML ASML is one of the world's leading manufacturers of chip-making equipment. Our vision is to enable affordable microelectronics that improve the quality of life. To achieve this, our mission is to invent, develop, manufacture and service advanced technology for high-tech lithography, metrology and software solutions for the semiconductor industry. ASML's guiding principle is continuing Moore's Law towards ever smaller, cheaper, more powerful and energy-efficient semiconductors. This results in increasingly powerful and capable electronics that enable the world to progress within a multitude of fields, including healthcare, technology, communications, energy, mobility, and entertainment. ASML is a multinational company with offices in 60 cities in 16 countries, headquartered in Veldhoven, the Netherlands. We employ more than 16,500 people on payroll and flexible contracts (expressed in full time equivalents). ASML is traded on Euronext Amsterdam and NASDAQ under the symbol ASML. More information about ASML, our products and technology, and career opportunities is available on www.asml.com. Forward Looking Statements This document contains statements relating to certain projections and business trends that are forward-looking, including statements with respect our partnership with Cadence Design Systems, Inc. and our intention to collaborate with Cadence on various holistic lithography initiatives, the benefits of our partnership with Cadence in respect of our holistic lithography product portfolio, and the further development and enhancement of holistic lithography products and tools. You can generally identify these statements by the use of words like "may", "will", "could", "should", "project", "believe", "anticipate", "expect", "plan", "estimate", "forecast", "potential", "intend", "continue" and variations of these words or comparable words. These statements are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about the business and our future financial results and readers should not place undue reliance on them. Forward-looking statements do not guarantee future performance and involve risks and uncertainties. These risks and uncertainties include, without limitation, the possibility that our partnership with Cadence fails to become successful or that it may not benefit our holistic lithography product portfolio as anticipated, product demand and semiconductor equipment industry capacity, worldwide demand and manufacturing capacity utilization for semiconductors (the principal product of our customer base), including the impact of general economic conditions on consumer confidence and demand for our customers' products, competitive products and pricing, the impact of any manufacturing efficiencies and capacity constraints, performance of our systems, the continuing success of technology advances and the related pace of new product development, our ability to enforce patents and protect intellectual property rights, the risk of intellectual property litigation, trade environment and other risks indicated in the risk factors included in ASML's Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission. These forward-looking statements are made only as of the date of this document. ASML does not undertake any obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
News Article | March 2, 2017
The Coalition for Adequate School Housing (CASH) and the American Institute of Architects California Council (AIACC) recently announced the Leroy F. Greene award winners at the CASH 38th Annual Conference. Two K-12 school projects designed by LPA Inc. were honored: Montgomery Middle School and the TIDE Academy. “We are especially honored to be recognized with CASH/AIACC Leroy F. Greene awards, which prioritize the collaboration between designers and educational partners,” explains Jim Kisel, AIA, Principal at LPA. He continues, “Our integrated design approach ensures that all stakeholders have a hand in the design and planning of a facility from the onset of the project, minimizing inefficiencies and maximizing energy and monetary savings. We’re grateful to be recognized for this beneficial process.” Montgomery Middle School was honored with an Award of Merit in the New Built category. The San Diego middle school, part of Sweetwater Union High School District, has a new two-story classroom building, featuring 18 classrooms, a library and media center, community-building cafeteria and student counseling center. A model for integrated sustainable design, the project features outdoor amenities, including a large central courtyard, landscaped stormwater bioswale and high-performance HVAC systems. The new campus has become a source of pride for students and families, creating a new legacy of technology-fluent, creative minds. Jurors said, “This LEED Platinum project includes notable sustainable features, and collaboration with the maintenance and operations to create more efficient classrooms demonstrates innovation.” Next, the TIDE Academy, which stands for technology, innovation, design and engineering and is formerly known as Menlo Park Small High School, received an Award of Honor in the Project in Design category. Located a quarter mile from the south end of the San Francisco Bay, this 45,000-square-foot public high school implements a project-based learning curriculum with a focus on college and career readiness in STEM fields. From classrooms to STEM labs, the varied learning spaces are stacked on three floors, and its L-shape configuration allows for a fluid indoor/outdoor connection. This intentional design cultivates flexibility for spontaneous learning opportunities while taking advantage of the excellent coastal climate. In addition to classroom spaces, the campus features a makerspace shop, a coding lab dedicated to computer code education and software development and a design lab for rapid prototyping and implementing design concepts. Reflecting its progressive curriculum, the school is designed with an industrial feel and a sustainable approach. LPA—who provides architectural, interiors, landscape, civil, structural and mechanical, electrical and plumbing engineering services—applies an integrated approach to maximize the school’s sustainability. With exposed structural elements, the building is organized to maximize exposure to daylight, as well as views to the bay. A large, perforated metal scrim shades the building, protecting it from direct glare and reducing solar heat gains. In addition, all stormwater is collected and treated on site with its native plant palette and bioretention planters. Finally, by increasing permeable surfaces on the campus, the runoff volume is significantly reduced. Jurors said, “This project in design includes a robust planning process that defines the characteristics of the learning profile of the school, and then imagined what environment would support this type of learner.” Both Montgomery Middle School and the TIDE Academy exemplify the benefits of an integrated design approach. Bringing educators, district staff, community members and designers together at the onset of the project to identify and solve challenges results in a highly efficient, elegant and educational design. LPA President Dan Heinfeld, FAIA, states, “Since 2005, LPA has been recognized with a CASH/AIACC award every year, an unmatched testimony to our clients and their faith in our integrated approach.” About LPA Founded in 1965, LPA has more than 350 employees with offices in San Antonio and Irvine, Sacramento, San Diego and San Jose, California. The firm provides services in architecture, sustainability, planning, interior design, landscape architecture, engineering and graphics. With a proven commitment to integrated sustainable design, LPA designs facilities that span from K-12 schools, colleges and universities to corporate, health care and civic establishments. More than 700 major design awards attest to LPA’s commitment to design excellence. For more information, visit http://www.lpainc.com. About AIACC The AIACC represents the interests of more than 11,000 architects and allied professionals in California. Founded in 1944, The AIACC's mission supports architects in their endeavors to improve the quality of life for all Californians by creating more livable communities, sustainable designs and quality work environments. Today, The AIACC is the largest component of the National AIA organization.
News Article | February 15, 2017
Rick D’Amato, Principal at LPA Inc., has been elected to the American Institute of Architects (AIA) College of Fellows as the fourth architect to be elevated from the integrated design firm. One of the highest individual achievements that the AIA recognizes, D’Amato joins the less than 3 percent of members to receive this honor. Working with civic agencies and corporate users in California, D’Amato has devoted his career to furthering the positive effect sustainable design can have on the built environment. With more than 30 years of design experience, and 25 years at LPA, he has accumulated more than 40 AIA design awards and numerous other industry awards. In his Fellowship nomination letter to the AIA, LPA President Dan Heinfeld states, “Rick’s award-winning work for these most public of projects provides important models of sustainability and how our public facilities can teach users and visitors alike about the importance of place.” Heinfeld adds, “His rigor and personal commitment to providing the best our profession has to offer for these important institutional places are a powerful testimony to how design can change lives.” One of D’Amato’s notable projects in his career is the Environmental Nature Center in Newport Beach, California—the first LEED Platinum project in Orange County, California. This project incorporates a simple yet dynamic structural form that is passively heated and cooled, and is also one of the first net-zero projects. Aggressive sustainable design strategies are used as educational tools for the students who interact with the facility. The project earned awards from the AIA California Chapter and Orange County Chapter. Additionally, D'Amato was integral in the design of the West Hollywood Automated Parking Garage—the first automated parking garage on the West Coast for a municipality. The fully-automated parking structure contains four bays for entry and exit as well as an outdoor community plaza area for community events. The structure provides a clean, environmentally-friendly alternative to conventional parking systems. Along with his passion for sustainability and pragmatic sense of design, D’Amato has lectured on design-build practices and public library design, sustainable design and progressive office design throughout the country. He currently serves on the board of the AIA Long Beach, South Bay Chapter as well as the Long Beach Memorial Navy Heritage Association. D’Amato will officially receive his new Fellowship distinction at the AIA’s National conference April 28 in Orlando, Florida. Humbled by the honor, D’Amato says, “It is truly an honor to be elected to the AIA College of Fellows. This is an organization which I respect and admire and a profession with which I am very proud to be a part. This, however, is an honor that must be shared with the amazing and talented individuals I have worked with throughout the years at LPA. I am continually inspired by their dedication and passion to their work.” For interview opportunities with Rick D’Amato, please contact Carina Calhoun at ccalhoun(at)lpainc(dot)com. About LPA Founded in 1965, LPA has more than 350 employees with offices in San Antonio and Irvine, Sacramento, San Diego and San Jose, California. The firm provides services in architecture, sustainability, planning, interior design, landscape architecture, engineering and graphics. With a proven commitment to integrated sustainable design, LPA designs facilities that span from K-12 schools, colleges and universities to corporate, health care and civic establishments. More than 700 major design awards attest to LPA’s commitment to design excellence. For more information, visit http://www.lpainc.com. About the College of Fellows The AIA College of Fellows seeks to stimulate a sharing of interests among Fellows, promote the purposes of the Institute, advance the profession of architecture, mentor young architects and be of ever-increasing service to society. The College of Fellows, founded in 1952, is composed of members of the Institute who are elected to Fellowship by a jury of their peers. Fellowship is one of the highest honors the AIA can bestow upon a member. Elevation to Fellowship not only recognizes the achievements of the architect as an individual but also elevates before the public and the profession those architects who have made significant contributions to architecture and to society.